HLA-A and neoplasm: Moreover, the post-vaccine PBMCs of two out of three patients also recognized an HLA-A*0201 matched NBL cell line in a HLA-Class I dependent fashion (Fig. 6), likely suggesting a potential reaction of vaccine-stimulated lymphocytes against patient tumor.